Dr. Hönle (HNL) Q4 2024 earnings summary

Executive summary

• Revenue declined 7.2% year-over-year to €98.7 million, mainly due to weak demand in machinery, equipment, and automotive sectors, with pronounced declines in the Curing business unit.

• Operating result (EBIT) was €-10.3 million, impacted by €10.3 million in non-recurring expenses from divestitures and write-downs; adjusted EBIT was €39k.

• Strategic restructuring focused on core UV technology, divestiture of non-core assets, and consolidation of production and R&D to improve efficiency.

• Acquisition of STERIXENE SAS expanded the Disinfection BU, adding pulsed UV light and microbiological testing capabilities.

Financial highlights

• EBITDA rose to €3.0 million from €0.3 million year-over-year; adjusted EBITDA was €5.5 million (prior year: €13.1 million).

• Net loss widened to €13.0 million (prior year: €10.9 million); earnings per share were €-2.19 (prior year: €-1.82).

• Operating cash flow increased to €7.7 million (prior year: €7.4 million); net cash from operating activities was €5.5 million.

• Total assets decreased 11.8% to €155.4 million; equity ratio at 51.3%.

• Goodwill write-downs of €7.7 million and inventory write-downs of €2.1 million were recorded.

Outlook and guidance

• Revenue for 2024/2025 projected between €95 million and €105 million; EBITDA expected to exceed 2023/2024 adjusted EBITDA due to cost controls.

• Management expects economic recovery only in the second half of 2025, with continued focus on core business and cost reduction.